The upstream industry for the R&D, production and sales of pharmaceutical intermediates is the basic chemical raw material industry, and the downstream industry is the chemical raw material medicine and chemical pharmaceutical preparation industry. The upstream of pharmaceutical intermediates is the basic chemical raw material industry. Basic chemical raw materials are bulk commodities, and their prices fluctuate greatly, which directly affects the production costs of enterprises. However, pharmaceutical intermediates are subdivided into primary intermediates and advanced intermediates. Because primary intermediate suppliers can only provide simple intermediate production, they are at the forefront of the industry chain and have the greatest competitive pressure and price pressure. The price fluctuations of basic chemical raw materials have a greater impact on them. The high-level intermediate suppliers not only have strong bargaining power with primary suppliers, but more importantly, because they are responsible for the production of high-tech intermediates and maintain closer ties with multinational companies. Fluctuations in raw material prices have little impact on it. The downstream industry of the pharmaceutical intermediate industry is mainly the API production industry, and APIs and preparations are in the relationship between the upstream and downstream industry chains, and the consumer demand for downstream preparations will directly affect the demand for APIs. With the improvement of people's living standards and the aging degree, the demand for medicines has been on the rise for a long time. Therefore, the transmission from finished medicines to bulk medicines has greatly promoted the demand for bulk medicines. Therefore, the growth of the global pharmaceutical market has largely affected the development of the entire intermediate and API industry.